2011 Cell Signaling Technology, Inc.

SignalSilence® Met siRNA I

10 μM in 300 μl (100 transfections)



Orders 877-616-CELL (2355)

orders@cellsignal.com

Support 877-678-TECH (8324)

info@cellsignal.com

Web www.cellsignal.com

rev. 02/16/16

For Research Use Only. Not For Use In Diagnostic Procedures.


Species Cross-Reactivity: H

Description: SignalSilence® Met siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit Met expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.

Background: Met, a high affinity tyrosine kinase receptor for hepatocyte growth factor (HGF, also known as scatter factor) is a disulfide-linked heterodimer made of 45 kDa α - and 145 kDa β -subunits (1.2). The α -subunit and the amino-terminal region of the β-subunit form the extracellular domain. The remainder of the β -chain spans the plasma membrane and contains a cytoplasmic region with tyrosine kinase activity. Interaction of Met with HGF results in autophosphorylation at multiple tyrosines, which recruit several downstream signaling components, including Gab1, c-Cbl. and PI3 kinase (3). These fundamental events are important for all of the biological functions involving Met kinase activity. The addition of a phosphate at cytoplasmic Tyr1003 is essential for Met protein ubiquitination and degradation (4). Phosphorylation at Tyr1234/1235 in the Met kinase domain is critical for kinase activation. Phosphorylation at Tyr1349 in the Met cytoplasmic domain provides a direct binding site for Gab1 (5). Altered Met levels and/or tyrosine kinase activities are found in several types of tumors, including renal, colon, and breast. Thus, Met is an attractive cancer therapeutic and diagnostic target (6,7).

Directions for Use: CST recommends transfection with 100 nM Met siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.

Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.



Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-), SignalSilence® Met siRNA I (+) or SignalSilence® Met siRNA II #6622 (+), using Met (25H2) Mouse mAb #3127 (upper) or α -Tubulin (11H10) Rabbit mAb #2125 (lower). The Met (25H2) Mouse mAb confirms silencing of Met expression, while the α -Tubulin (11H10) Rabbit mAb is used to control for loading and specificity of Met siRNA.

Entrez-Gene ID #4233 Swiss-Prot Acc. #P08581

Storage: Met siRNA I is supplied in RNAse-free water. Aliquot and store at -20° C.

Please visit www.cellsignal.com for a complete listing of recommended companion products.

Background References:

- (1) Cooper, C.S. et al. Nature 311, 29-33.
- (2) Bottaro, D.P. et al. (1991) Science 251, 802-4.
- (3) Bardelli, A. et al. (1997) Oncogene 15, 3103-11.
- (4) Taher, T.E. et al. (2002) J Immunol 169, 3793-800.
- (5) Schaeper, U. et al. (2000) J Cell Biol 149, 1419-32.
- (6) Eder. J.P. et al. (2009) Clin Cancer Res 15, 2207-14.
- (7) Sattler, M. and Salgia, R. (2009) *Update Cancer Ther* 3, 109-118.